Table 5.
Clinical study results: summary
| Efficacy variable | Group 1 | Group 2 | ||||||
| Nimotuzumab + CT + RT | CT + RT | p-value | Hazard ratio | Nimotuzumab + RT | RT | p value | Hazard ratio | |
| Overall Response Rate (at 24 weeks) | 100% (20) | 70% (14) | 0.020 | 76% (13) | 40% (7) | 0.023 | ||
| Median Progression Free survival (at 30 months) | NA | 12.66 | 0.0132 | 0.373 | 10.09 | 6.9 | 0.2429 | 0.666 |
| (24.42, NA) | (6.44, 25.12) | (4.31, NA) | (5.39, 8.97) | |||||
| Progression Free Survival Rate (%) (at 30 months) | 56.52 | 21.74 | 0.0157 | 34.78 | 13.04 | 0.0839 | ||
| Median Disease Free survival (at 30 months) | NA | 25.02 | 0.0251 | 0.311 | NA | 8.33 | 0.1639 | 0.489 |
| (12.66, NA) | (16.17, NA) | (6.18, NA) | ||||||
| Disease Free Survival Rate (%) (at 30 months) | 56.52 | 21.74 | 0.0157 | 34.78 | 13.04 | 0.0839 | ||
| Median Overall Survival (at 30 months) | NA | 21.96 | 0.0036 | 0.266 | 14.37 | 12.79 | 0.7079 | 0.868 |
| (6.77, 29.95) | (4.83, NA) | (6.18, 23.31) | ||||||
| Overall Survival Rate (%) (at 30 months) | 69.57 | 21.74 | 0.0011 | 39.13 | 21.74 | 0.1999 | ||
Note: The 95% CI are mentioned in brackets. The 95% confidence intervals for the median survival were computed using 25th percentile as a lower confidence limit and 75th percentile as an upper confidence limit. NA, Not Available. In the Overall Response Rate, the number in brackets is the number of evaluable patients.